ZA928140B - Compositions and methods for therapy and prevention of cancer, aids and anemia - Google Patents
Compositions and methods for therapy and prevention of cancer, aids and anemiaInfo
- Publication number
- ZA928140B ZA928140B ZA928140A ZA928140A ZA928140B ZA 928140 B ZA928140 B ZA 928140B ZA 928140 A ZA928140 A ZA 928140A ZA 928140 A ZA928140 A ZA 928140A ZA 928140 B ZA928140 B ZA 928140B
- Authority
- ZA
- South Africa
- Prior art keywords
- anemia
- aids
- cancer
- therapy
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/779,744 US6037376A (en) | 1991-10-21 | 1991-10-21 | Methods for therapy of cancer |
CA002108963A CA2108963C (fr) | 1991-10-21 | 1993-10-21 | Compositions et methodes de traitement et de prevention du cancer, du sida et de l'anemie |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA928140B true ZA928140B (en) | 1994-04-21 |
Family
ID=25676774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA928140A ZA928140B (en) | 1991-10-21 | 1992-10-21 | Compositions and methods for therapy and prevention of cancer, aids and anemia |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0567613B1 (fr) |
AU (1) | AU2804592A (fr) |
CA (1) | CA2108963C (fr) |
WO (1) | WO1993007866A2 (fr) |
ZA (1) | ZA928140B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
US7910624B1 (en) | 1995-03-03 | 2011-03-22 | The Trustees Of Boston University | Compositions for the treatment of blood disorders |
US5783605A (en) * | 1995-02-27 | 1998-07-21 | Kuo; Sheng-Chu | Helper inducers for differentiation therapy and chemoprevention of cancer |
US6011000A (en) * | 1995-03-03 | 2000-01-04 | Perrine; Susan P. | Compositions for the treatment of blood disorders |
EP1886677A1 (fr) * | 1996-07-26 | 2008-02-13 | Susan P. Perrine | Composition comprenant un agent d'induction et agent antiviral pour le traitement de maladies sanguines, virales et cellulaires |
US6197743B1 (en) | 1996-07-26 | 2001-03-06 | The Trustees Of Boston University | Compositions and methods for the treatment of viral disorders |
US6110955A (en) * | 1997-03-11 | 2000-08-29 | Beacon Laboratories, Inc. | Metabolically stabilized oxyalkylene esters and uses thereof |
US5939455A (en) * | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
CA2324426A1 (fr) | 1998-02-11 | 1999-08-19 | Douglas V. Faller | Compositions et techniques de traitement de la mucoviscidose |
EP1291015A1 (fr) | 2001-09-10 | 2003-03-12 | Lunamed AG | Compositions à libération prolongée d'un agent actif |
US20070004805A1 (en) * | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
US8101660B2 (en) | 2006-08-16 | 2012-01-24 | AmDerma Pharmaceuticals, LLC | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer |
WO2011038224A1 (fr) | 2009-09-24 | 2011-03-31 | Trustees Of Boston University | Procédés pour le traitement de troubles viraux |
WO2011072086A1 (fr) | 2009-12-08 | 2011-06-16 | Hemaquest Pharmaceuticals, Inc. | Procédés et régimes à faible dose pour traiter des troubles des globules rouges |
WO2011113013A2 (fr) | 2010-03-11 | 2011-09-15 | Hemaquest Pharmaceuticals, Inc. | Procédés et compositions pour le traitement d'états viraux ou induits par des virus |
EP2599482A1 (fr) | 2011-11-30 | 2013-06-05 | Lunamed AG | Application thérapeutique à faible dose de triglycéryl-(4-phénylbutyrate) |
EP2698156A1 (fr) * | 2012-08-16 | 2014-02-19 | Lunamed AG | Acide phénylbutyrique pour la chimiprévention |
US20220226322A1 (en) | 2019-05-31 | 2022-07-21 | Viracta Subsidiary, Inc. | Methods of treating virally associated cancers with histone deacetylase inhibitors |
WO2024165757A1 (fr) | 2023-02-10 | 2024-08-15 | Ludwig-Maximilians-Universität München | Phénylbutyrate oral pour le traitement de tauopathies à 4 répétitions humaines |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1511645A (en) * | 1974-05-31 | 1978-05-24 | Univ Ife | Sickle cell anaemia treatment |
US4470970A (en) * | 1981-07-02 | 1984-09-11 | Burzynski Stanislaw R | Purified antineoplaston fractions and methods of treating neoplastic disease |
-
1992
- 1992-10-13 AU AU28045/92A patent/AU2804592A/en not_active Abandoned
- 1992-10-13 EP EP92922550A patent/EP0567613B1/fr not_active Expired - Lifetime
- 1992-10-13 WO PCT/US1992/008875 patent/WO1993007866A2/fr active IP Right Grant
- 1992-10-21 ZA ZA928140A patent/ZA928140B/xx unknown
-
1993
- 1993-10-21 CA CA002108963A patent/CA2108963C/fr not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO1993007866A2 (fr) | 1993-04-29 |
EP0567613B1 (fr) | 2002-02-20 |
AU2804592A (en) | 1993-05-21 |
CA2108963C (fr) | 1999-03-16 |
EP0567613A4 (en) | 1996-03-13 |
WO1993007866A3 (fr) | 1993-05-27 |
CA2108963A1 (fr) | 1995-04-22 |
EP0567613A1 (fr) | 1993-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA928140B (en) | Compositions and methods for therapy and prevention of cancer, aids and anemia | |
IL104981A0 (en) | Antitumor compositions and methods of treatment | |
AU1980995A (en) | Methods and compositions for treatment of breast cancer | |
IL117873A0 (en) | Pharmaceutical compositions for inhibiting the growth of viruses and cancers | |
IL117876A0 (en) | Pharmaceutical compositions for inhibiting the growth of viruses and cancers | |
EP0596962A4 (en) | Therapeutic compositions and methods. | |
AU8044491A (en) | Antitumor compositions and methods of treatment | |
IL107449A0 (en) | Compositions and methods for reducing toxicity and increasing the efficacy of drugs | |
AU626005B1 (en) | Treatment of endometriosis | |
EP0656791A4 (fr) | Compositions et methodes therapeutiques a base de 2,7,9-tricarboxy-pyrroloquinoleine (pqq). | |
IL114119A0 (en) | Compositions and methods for the treatment of tumors | |
IL101245A0 (en) | Pharmaceutical compositions for the treatment of prostatic cancer | |
IL101410A0 (en) | Formulation for the treatment of cancer | |
AU7770991A (en) | Method and composition for the treatment of cancer | |
GB9101238D0 (en) | Treated powder | |
HUP9802536A3 (en) | Pharmaceutical compositions containing 1,2,4-benzotriazine 1,4-dioxide and use thereof for the preparation of pharmaceutical compositions treating cancer | |
IL106763A0 (en) | Pharmaceutical compositions for treating cancer | |
GB9105979D0 (en) | Treated powder | |
GB2312375B (en) | Agents for treatment of cancer | |
GB9211396D0 (en) | Cancer therapy and compositions for use therein | |
GB9112552D0 (en) | Method and composition for the treatment of cancer | |
GB9123572D0 (en) | Pharmaceutical compositions and methods for the treatment of malignancy | |
GB9117210D0 (en) | Treatment of cancer | |
GB9226032D0 (en) | Treatment of cancer | |
AU2823392A (en) | Treatment of nephritis |